Therefore, administration of chemotherapy in eligible patients as the first step prior to the initiation of osimertinib should be considered the standard of care for patients with early-stage EGFR mutant lung cancer after surgical resection (15). The gene discussed is EGFR; the disease is lung carcinoma.